Abstract
Background Long COVID symptoms occur for a proportion of acute COVID-19 survivors, with reduced risk among the vaccinated, and for Omicron compared to Delta variant infections. The health loss attributed to pre-Omicron long COVID has previously been estimated using only a few major symptoms.
Methods The years lived with disability (YLDs) due to long COVID in Australia during the 2021-2022 Omicron BA.1/BA.2 wave were calculated using inputs from previously published case-control, cross-sectional, or cohort studies examining the prevalence and duration of individual long COVID symptoms. This estimated health loss was compared with acute SARS-CoV-2 infection YLDs and years of life lost (YLLs) from SARS-CoV-2. The sum of these three components equals COVID-19 disability-adjusted life years (DALYs); this was compared to DALYs from other diseases.
Results 5200 (95% uncertainty interval [UI] 2200-8300) YLDs were attributable to long COVID and 1800 (95% UI 1100-2600) to acute SARS-CoV-2 infection, suggesting long COVID caused 74% of the overall YLDs from SARS-CoV-2 infections in the BA.1/BA.2 wave. Total DALYs attributable to SARS-CoV-2 were 50 900 (95% UI 21 000-80 900), 2.4% of expected DALYs for all diseases in the same period.
Conclusion This study provides a comprehensive approach to estimating the morbidity due to long COVID. Improved data on long COVID symptoms will improve the accuracy of these estimates. As data accumulates on SARS-CoV-2 infection sequelae (e.g., increased cardiovascular disease rates), total health loss is likely to be higher than estimated in this study. Nevertheless, this study demonstrates that long COVID requires consideration in pandemic policy planning given it is responsible for the majority of direct SARS-CoV-2 morbidity, including during an Omicron wave in a highly vaccinated population.
Key messages
Our study is the first to comprehensively estimate long COVID morbidity using its individual symptoms, during Australia’s 2021-2022 Omicron wave.
We show that long COVID contributed to almost three-quarters of the non-fatal health loss resulting from Omicron infections in this period.
Long COVID contributes to a substantial proportion of direct COVID-19 morbidity, even in a highly vaccinated population during an Omicron wave. It should therefore be more explicitly considered in future pandemic policymaking.
Our method of estimating long COVID morbidity has explicable differences to existing long COVID burden of disease approaches and may provide a more accurate estimate of the morbidity attributable to long COVID.
Competing Interest Statement
The Population Interventions research group is expected to receive payment from Moderna Inc. to fund research into COVID-19 vaccine effectiveness in Victoria, Australia. The authors declare no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study did not include patient or public involvement, using only already published literature.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Methods section on morbidity calculation updated to provide further clarification on assumptions made. A flow diagram has also been added (now Figure 1) to add to this section further detail to morbidity calculations method. Table 2 has been moved to the supplement. An additional sensitivity analysis testing one of the main assumptions for morbidity calculations has been added to the methods and included in the discussion. An additional paragraph has been added to the discussion to improve understanding of the main results.
Data Availability
All data/sources used for quantitative analysis can be made available by authors on reasonable request.
